<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682457</url>
  </required_header>
  <id_info>
    <org_study_id>2003962</org_study_id>
    <nct_id>NCT04682457</nct_id>
  </id_info>
  <brief_title>Defining the Decline in Endogenous Insulin Secretion in Type 1 Diabetes Diagnosed After 30 Years of Age.</brief_title>
  <acronym>DROPLeT</acronym>
  <official_title>Defining the Decline in Endogenous Insulin Secretion in Type 1 Diabetes Diagnosed After 30 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Devon and Exeter NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Devon and Exeter NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims is to find out if people with type 1 diabetes diagnosed in later life (after&#xD;
      age 30) have the same rapid loss of insulin secretion (measured using C-peptide) that occurs&#xD;
      in younger adults with type 1 diabetes. The investigators will recruit 135 participants aged&#xD;
      over 30 years with a clinical diagnosis of type 1 diabetes and diabetes duration ≤100 days.&#xD;
      The investigators will also recruit a comparison group of 61 participants aged 18-30 with a&#xD;
      clinical diagnosis of type 1 diabetes and diabetes duration ≤100 days. C-peptide will be&#xD;
      measured during mixed meal tolerance tests (MMTT) performed at baseline, 6 months and a year.&#xD;
&#xD;
      This study also aims to test a new more practical way of monitoring insulin secretion at home&#xD;
      using a finger prick 'blood spot' rather than time consuming tests in a hospital.&#xD;
      Finger-prick C-peptide samples will be collected after the MMTT and by the participants at&#xD;
      home throughout the year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to evaluate progression of type 1 diabetes. Primary analysis will be conducted&#xD;
      on those with &gt;=1 diabetes autoantibody positive (GAD, IA2 ZNT8). Sensitivity analysis will&#xD;
      be performed by repeating all analysis defining T1D as a) double antibody positivity and b)&#xD;
      single antibody positivity combined with a high genetic risk score for T1D (T1DGRS&gt;5th&#xD;
      centile of a control population).&#xD;
&#xD;
      Further aims will be to evaluate the utility of dried blood spot testing to detect change in&#xD;
      C-peptide and the utility of home test results as a marker of hypoglycaemia and glucose&#xD;
      variability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide value at a year</measure>
    <time_frame>12 months</time_frame>
    <description>12 month (Mixed Meal Tolerance Test) MMTT area under the curve (AUC) C-peptide.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in C-peptide over a year</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of change of MMTT AUC C-peptide over 12 months assessed at regular study visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-peptide value at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Mean C-peptide at 12 months assessed using MMTT and home blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability &amp; hypoglycemia</measure>
    <time_frame>12 months</time_frame>
    <description>Glucose variability &amp; hypoglycemia as measured by continuous glucose monitoring (CGM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dried blood spot C-peptide</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of change in home dried blood spot C-peptide over 12 months</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Progression</condition>
  <arm_group>
    <arm_group_label>Late Onset</arm_group_label>
    <description>Participants diagnosed with Type 1 diabetes at over 30 years of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18 to 30</arm_group_label>
    <description>Participants diagnosed with Type 1 diabetes between 18 and 30 years of age</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Plasma, DNA,&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Recent clinical diagnosis of type 1 diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with a clinical diagnosis of Type 1 diabetes within the previous 100 days.&#xD;
&#xD;
          -  Aged &gt;30 at the time of Type 1 diabetes diagnosis OR (additional early onset Type 1&#xD;
             diabetes cohort) aged ≥18 and ≤30 at the time of Type 1 diabetes diagnosis.&#xD;
&#xD;
          -  Insulin treated at the time of recruitment&#xD;
&#xD;
          -  Able and willing to provide informed consent.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known monogenic diabetes&#xD;
&#xD;
          -  Known secondary diabetes (diabetes considered likely due to medication, cystic&#xD;
             fibrosis, pancreatitis, pancreatic cancer, pancreatic surgery, hemochromatosis or&#xD;
             Cushing's syndrome).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angus Jones, MBBS MRCP</last_name>
    <role>Study Director</role>
    <affiliation>NIHR Exeter Clinical Research Facility</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Thomas, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIHR Exeter Clinical Research Facility</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anita Hill</last_name>
    <phone>01392408184</phone>
    <email>Anita.Hill2@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Tippett</last_name>
    <phone>01392408184</phone>
    <email>rde-tr.DiabetesResearch@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Thomas, MRCP</last_name>
      <email>n.thomas3@exeter.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Anita Hill</last_name>
      <phone>+44 (0) 1392 408184</phone>
      <email>Anita.Hill2@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Angus G Jones, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Thomas, MRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

